Health · Medical Research · 1 day ago

CG Oncology bladder treatment cut tumor recurrence risk by 68% in trial

CG Oncology bladder treatment cut tumor recurrence risk by 68% in trial

CG Oncology reported positive Phase 3 results for its bladder cancer treatment, cretostimogene.

The randomized trial enrolled 367 patients with intermediate-risk bladder cancer, a localized form of the disease.

The treatment reduced recurrence risk by 68% compared with current medical practice.

Cretostimogene is made from an engineered common cold virus and is delivered directly into the bladder through a catheter.

Patients are usually monitored every three months after their tumors are removed with minimally invasive surgery, and recurrence can mean more procedures over time.

The results may change how doctors treat some patients with bladder cancer, but no further next steps were stated.

3 sources

Related